Answers are grounded in this paper and cite their sources.
Most nirsevimab effectiveness estimates come from test-negative designs, which restrict populations to those seeking healthcare and testing. We estimated nirsevimab effectiveness among infants six months post-receipt using a target trial emulation with an estimand aligned to phase 3 trials. We emulated a target trial among infants born from February 2, 2023 through May 30, 2026, using electronic medical records at Kaiser Permanente Georgia. Using a g-computation estimator with Cox models fit separately in nirsevimab recipients and non-recipients, we estimated the cumulative incidence of RSV hospitalization and medically-attended RSV at 30-day intervals through 180 days post-receipt. Among 4,826 infants, nirsevimab reduced the risk of RSV hospitalization by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) at 180 days post-receipt. The number needed to immunize to prevent one case was 147 (95% CI: 94 to 333) for RSV hospitalization and 39 (95% CI: 28 to 68) for medically-attended RSV. Nirsevimab was effective through 180 days post-receipt. This cohort-based emulation avoids conditioning on testing and the restricted generalizability of the test-negative and matching-based designs that dominate the literature. These findings support continued nirsevimab use to protect infants against RSV.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: